Table 4.
Adverse event | Number of dogs monitored | Adverse event occurred during darbepoetin treatment | Intervention for adverse event deemed warranted | Darbepoetin discontinued |
---|---|---|---|---|
Increase in systolic blood pressure | 25 | 24 | 13 | 0 |
Hyperkalemia (>5.2 mmol/L) | 33 | 14 | 0 | 0 |
Thrombocytosis (>530,000/μL) | 23 | 4 | 0 | 0 |
Polycythemia (packed cell volume >60%) | 33 | 0 | 0 | 0 |
Seizures | 33 | 5 | 2 | 0 |
Diarrhea | 33 | 3 | 0 | 0 |
Vomiting | 33 | 3 | 0 | 0 |
Cutaneous reaction | 33 | 0 | 0 | 0 |
Hypersensitivity reaction to darbepoetin | 33 | 0 | 0 | 0 |
Hypersensitivity reaction to iron dextran | 33 | 1 | 1 | 0 |
Pure red cell aplasia suspected | 33 | 2 | 2 | 2 |